U.S. flag An official website of the United States government
  1. Home
  2. Food
  3. News & Events from CFSAN
  4. Workshops, Meetings & Webinars on Food and Dietary Supplements
  5. Public Meeting to Discuss the Development of a List of Pre-DSHEA Dietary Ingredients
  1. Workshops, Meetings & Webinars on Food and Dietary Supplements

Public Meeting to Discuss the Development of a List of Pre-DSHEA Dietary Ingredients

The FDA held a public meeting, Development of a List of Dietary Ingredients that Pre-Date the Dietary Supplement Health and Education Act of 1994 (DSHEA), to discuss the development of a list of pre-DSHEA dietary ingredients.

October 3, 2017
8:00am – 5:00pm

Center for Food Safety and Applied Nutrition
U.S. Food and Drug Administration
Wiley Auditorium
5001 Campus Drive
College Park, MD 20740

The purpose of the meeting is to give interested stakeholders an opportunity to discuss issues related to FDA’s planned development of a list of pre-DSHEA ingredients. Topics covered during the meeting will include what evidence is necessary to show that an ingredient was marketed before October 15, 1994, and what process should be used to develop the list. FDA invites interested parties to provide information, share perspectives, and raise issues specifically related to the evidence needed to demonstrate that an ingredient is pre-DSHEA and on the process by which ingredients should be added to the list. Parties who are unable to participate in person will be able to join the meeting via live webcast.

For general questions about the meeting, contact:
Juanita Yates
Center for Food Safety and Applied Nutrition (HFS-009)
Food and Drug Administration
5001 Campus Dr.
College Park, MD 20740
phone: 240-402-1731
email: [email protected].

For more information about the meeting, see the Federal Register notice and the additional links provided below.

Meeting Materials

Commenting

The FDA accepted public comments September 6, 2017 through December 4, 2017. View comments submitted electronically on regulations.gov in docket folder FDA-2017-N-4625.

Additional Information

Back to Top